Additional Advancements in Pipeline
Vertex expects to begin clinical development of a novel janus
kinase 3 (JAK3)
inhibitor, VX-509, with broad potential in the treatment of multiple immune-mediated inflammatory diseases, in mid-2008.
In the second quarter, Vertex’s collaborator, Merck & Co., Inc., is expected to initiate a Phase 1 clinical trial of the Aurora kinase inhibitor MK-5108 (VX-689) in patients with advanced and/or refractory tumors.